A Study of T-Cell Therapy (IMA203/IMA203CD8) in People With Solid Tumors

Full Title

Phase 1/2 Study Evaluating Genetically Modified Autologous T-cells Expressing a T-cell Receptor Recognizing a Cancer/germline Antigen as Monotherapy or in Combination with Nivolumab in Patients with Recurrent and/or Refractory Solid Tumors (ACTengineTM IMA203-101)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Alexander Shoushtari’s office at 646-608-2091.